Bone health in people with epilepsy: Is it impaired and what are the risk factors?

Seizure

Volumn 17, Issue 2, 2008, Pages 181-186

  Pack, Alison ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Antiepileptic drugs; Bone; Epilepsy

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; COLECALCIFEROL; CYTOCHROME P450; ETIRACETAM; IBANDRONIC ACID; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RISEDRONIC ACID; TOPIRAMATE; VALPROIC ACID; VITAMIN D; XENOBIOTIC AGENT; ZONISAMIDE;

BONE DENSITOMETRY; BONE DISEASE; BONE TURNOVER; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG MEGADOSE; EPILEPSY; FRACTURE; GLAUCOMA; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MINERAL METABOLISM; OBESITY; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION;

ANTICONVULSANTS; BONE DENSITY; BONE DISEASES; EPILEPSY; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS;

EID: 38949186741     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.11.020     Document Type: Review

References (32)

1. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general (2004), U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
2. Weinstein R.S., Bryce G.F., Sappington L.J., King D.W., and Gallagher B.B. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58 (1984) 1003-1009
3. Andress D.L., Ozuna J., Tirschwell D., Grande L., Johnson M., Jacobson A.F., et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59 (2002) 781-786
4. Pack A.M., Morrell M.J., Marcus R., Holloway L., Flaster E., Doñe S., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57 (2005) 781-786
5. Verrotti A., Greco R., Morgese G., and Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47 (2000) 385-388
6. Verrotti A., Greco R., Latini G., Morgese G., and Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43 (2002) 1488-1492
7. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 (2001) 445-449
8. Sheth R.D. Bone health in pediatric epilepsy. Epilepsy Behav 5 Suppl. 2 (2004) S30-S35
9. Pack A.M., and Morrell M.J. Epilepsy and bone health in adults. Epilepsy Behav 5 Suppl. 2 (2004) S24-S29
10. Petty S.J., Paton L.M., O'Brien T.J., Makovey J., Erbas B., Sambrook P., et al. Effect of antiepileptic drug medication on bone mineral measures. Neurology 65 (2005) 1358-1365
11. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., and Stone K.L. Antiepileptic drug increases rates of bone loss in older women: a prospective study. Neurology 62 (2004) 2051-2057
12. Vestergaard P. Epilepsy, osteoporosis, and fracture risk-a meta-analysis. Acta Neurol Scandanavia 112 (2005) 277-286
13. Nissen-Meyer L.S., Svalheim S., Taubøll E., Reppe S., Lekva T., Solberg L.B., et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 48 (2007) 1850-1860
14. Mattson R.H., and Gidal B.E. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 5 Suppl. 2 (2004) S36-S40
15. Espallargues M., Sampietro-Colom L., Estrada M.D., Solà M., del Rio L., Setoain J., et al. Identifying bone-mass related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature. Osteopor Int 12 (2001) 811-822
16. Souverein P.C., Webb D.J., Petri H., Weil J., Van Staa T.P., and Egberts T. Incidence of fractures among epilepsy patients: a population-based study retrospective cohort study in the General Research Database. Epilepsia 46 (2005) 304-310
17. Souverein P.C., Webb D.J., Weil J.G., Van Staa T.P., and Egberts A.C. Use of antiepileptic drugs and risk of fractures: case control study among patients with epilepsy. Neurology 66 (2006) 1318-1324
18. Kim S.H., Lee J.W., Choi K.G., Chung H.W., and Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 10 2 (2007) 291-295
19. Mintzer S., Boppana P., Toguri J., and DeSantis A. Vitamin D levels and bone turnover in epilepsy taking carbamazepine or oxcarbazepine. Epilepsia 47 3 (2006) 510-515
20. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127 2 (1995) 256-262
21. Gou C.Y., Ronen G.M., and Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 9 (2001) 1141-1147
22. Pierce Jr. W.M., Nardin G.F., Fuqua M.F., Sabah-Maren E., and Stern S.H. Effect of chronic carbonic anhydrase inhibitor therapy on bone and mineral density in white women. J Bone Miner Res 6 4 (1991) 347-354
23. Leung A., and Ramsay E. Effect of topiramate on bone resorption in adults. Am Epilepsy Soc, Abstr 2 (2006) 150
24. Ali I.I., Herial N.A., Horrigan T., Kellough L., and Tietjen G.E. Measurement of bone mineral density in patients on levetiracetam monotherapy. Am Epilepsy Soc, Abstr 3 (2006) 211
25. Pascussi J.M., Robert A., Nguyen M., Walrant-Debray O., Garabedian M., Martin P., et al. Possible involvement or pregnane X receptor-enhanced CYP 24 expression in drug-induced osteomalacia. J Clin Invest 115 1 (2005) 177-186
26. Zhou C., Assem M., Tay J.C., Watkins P.B., Blumberg B., Schuetz E.G., et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116 6 (2006) 1703-1712
27. von Borstel Smith M., Crofoot K., Rodriguez-Proteau R., and Filtz T.M. Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. Toxicol In Vitro 21 5 (2007) 855-862
28. Fitzpatrick L.A. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5 Suppl. 2 (2004) S3-S15
29. Elliott J.O., Jacobsen M.P., and Haneef Z. Homocysteine and bone loss in epilepsy. Seizure 16 1 (2007) 22-34
30. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. New Engl J Med 332 12 (1995) 767-773
31. Harden C.L., Herzog A.G., Nikolov B.G., Koppel B.S., Christos P.J., Fowler K., et al. Hormone replacement therapy in women with epilepsy: a randomized double-blind, placebo-controlled study. Epilepsia 47 9 (2006) 1447-1451
32. Mikati M.A., Dib L., Yamout B., Sawaya R., Rahi A.C., and Fuleihan G.-H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 67 11 (2006) 2005-2014